NO20015063D0 - En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten - Google Patents
En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transportenInfo
- Publication number
- NO20015063D0 NO20015063D0 NO20015063A NO20015063A NO20015063D0 NO 20015063 D0 NO20015063 D0 NO 20015063D0 NO 20015063 A NO20015063 A NO 20015063A NO 20015063 A NO20015063 A NO 20015063A NO 20015063 D0 NO20015063 D0 NO 20015063D0
- Authority
- NO
- Norway
- Prior art keywords
- inhibitor compound
- bile acid
- ileum
- ileal
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901387A SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | New pharmaceutical foromaulations |
PCT/SE2000/000755 WO2000062810A1 (en) | 1999-04-19 | 2000-04-19 | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20015063D0 true NO20015063D0 (no) | 2001-10-18 |
NO20015063L NO20015063L (no) | 2001-10-18 |
Family
ID=20415263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015063A NO20015063L (no) | 1999-04-19 | 2001-10-18 | En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1173205B1 (de) |
JP (1) | JP2002542208A (de) |
KR (1) | KR20010108516A (de) |
CN (1) | CN1348384A (de) |
AT (1) | ATE296641T1 (de) |
AU (1) | AU767425B2 (de) |
BR (1) | BR0009835A (de) |
CA (1) | CA2379105A1 (de) |
CZ (1) | CZ20013743A3 (de) |
DE (1) | DE60020551T2 (de) |
DK (1) | DK1173205T3 (de) |
EE (1) | EE04607B1 (de) |
ES (1) | ES2241603T3 (de) |
HK (1) | HK1042850A1 (de) |
HU (1) | HUP0200793A3 (de) |
IL (1) | IL145871A0 (de) |
IS (1) | IS2161B (de) |
NO (1) | NO20015063L (de) |
NZ (1) | NZ514264A (de) |
PL (1) | PL351186A1 (de) |
PT (1) | PT1173205E (de) |
SE (1) | SE9901387D0 (de) |
SI (1) | SI1173205T1 (de) |
SK (1) | SK15282001A3 (de) |
TR (1) | TR200103033T2 (de) |
WO (1) | WO2000062810A1 (de) |
ZA (1) | ZA200108539B (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002060415A1 (de) * | 2001-01-31 | 2002-08-08 | Röhm GmbH & Co. KG | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
BRPI0212346B1 (pt) | 2001-09-08 | 2016-02-02 | Albireo Ab | Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica. |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
CA2724384A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
CN102316872B (zh) | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
EP2364161B1 (de) | 2008-11-26 | 2020-03-11 | Satiogen Pharmaceuticals, Inc. | Zusammensetzungen mit satiogenen und anwendungsverfahren |
GB0900350D0 (en) * | 2009-01-09 | 2009-02-11 | Cambridge Entpr Ltd | Formulations of viable bacteria for oral delivery |
CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
WO2011142858A2 (en) | 2010-05-11 | 2011-11-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
EP3400944B1 (de) | 2010-11-08 | 2020-07-15 | Albireo AB | Ibat-hemmer zur behandlung von lebererkrankungen |
WO2012064267A1 (en) * | 2010-11-08 | 2012-05-18 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
EP2770990A4 (de) * | 2011-10-28 | 2015-03-11 | Lumena Pharmaceuticals Inc | Gallensäurerückflusshemmer zur behandlung von hypercholämie und cholestatischer lebererkrankung |
SG10201407013QA (en) * | 2011-10-28 | 2014-12-30 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
CA2913127A1 (en) | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
US10709755B2 (en) | 2014-06-25 | 2020-07-14 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
CN105362244A (zh) * | 2015-11-26 | 2016-03-02 | 青岛海之源智能技术有限公司 | 考来烯胺缓释片及制备方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3413878B1 (de) | 2016-02-09 | 2021-04-14 | Albireo AB | Orale cholestyraminformulierungen und verwendung davon |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3413877B1 (de) | 2016-02-09 | 2021-04-07 | Albireo AB | Orale cholestyraminformulierungen und verwendung davon |
EP3664782A1 (de) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyraminpellets, orale cholestyraminformulierungen und ihre verwendung |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
KR20210024033A (ko) | 2018-06-20 | 2021-03-04 | 알비레오 에이비 | 오데빅시바트의 약학 제제 |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
HRP20230039T1 (hr) | 2019-02-06 | 2023-06-09 | Albireo Ab | Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina |
ES2955799T3 (es) | 2019-02-06 | 2023-12-07 | Albireo Ab | Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares |
CN114072152A (zh) | 2019-02-12 | 2022-02-18 | 米鲁姆制药公司 | 患有胆汁盐输出泵缺乏症的患者对asbti的基因型和剂量依赖性应答 |
FI4069360T3 (fi) | 2019-12-04 | 2024-02-20 | Albireo Ab | Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
EP4069359B1 (de) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren |
WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4243831A1 (de) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat zur behandlung von progressiver familiärer intrahepatischer cholestase (pfic) |
EP4255565A1 (de) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2024121434A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA941003B (en) * | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
TW289020B (de) * | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
-
1999
- 1999-04-19 SE SE9901387A patent/SE9901387D0/xx unknown
-
2000
- 2000-04-19 WO PCT/SE2000/000755 patent/WO2000062810A1/en not_active Application Discontinuation
- 2000-04-19 ES ES00928046T patent/ES2241603T3/es not_active Expired - Lifetime
- 2000-04-19 PL PL00351186A patent/PL351186A1/xx not_active Application Discontinuation
- 2000-04-19 AT AT00928046T patent/ATE296641T1/de not_active IP Right Cessation
- 2000-04-19 DE DE60020551T patent/DE60020551T2/de not_active Expired - Fee Related
- 2000-04-19 TR TR2001/03033T patent/TR200103033T2/xx unknown
- 2000-04-19 HU HU0200793A patent/HUP0200793A3/hu unknown
- 2000-04-19 BR BR0009835-3A patent/BR0009835A/pt not_active IP Right Cessation
- 2000-04-19 AU AU46335/00A patent/AU767425B2/en not_active Ceased
- 2000-04-19 SK SK1528-2001A patent/SK15282001A3/sk not_active Application Discontinuation
- 2000-04-19 SI SI200030695T patent/SI1173205T1/xx unknown
- 2000-04-19 NZ NZ514264A patent/NZ514264A/en unknown
- 2000-04-19 JP JP2000611946A patent/JP2002542208A/ja active Pending
- 2000-04-19 EE EEP200100545A patent/EE04607B1/xx not_active IP Right Cessation
- 2000-04-19 EP EP00928046A patent/EP1173205B1/de not_active Expired - Lifetime
- 2000-04-19 CA CA002379105A patent/CA2379105A1/en not_active Abandoned
- 2000-04-19 KR KR1020017013297A patent/KR20010108516A/ko not_active Application Discontinuation
- 2000-04-19 CN CN00806493A patent/CN1348384A/zh active Pending
- 2000-04-19 PT PT00928046T patent/PT1173205E/pt unknown
- 2000-04-19 IL IL14587100A patent/IL145871A0/xx unknown
- 2000-04-19 CZ CZ20013743A patent/CZ20013743A3/cs unknown
- 2000-04-19 DK DK00928046T patent/DK1173205T3/da active
-
2001
- 2001-10-16 IS IS6109A patent/IS2161B/is unknown
- 2001-10-17 ZA ZA200108539A patent/ZA200108539B/en unknown
- 2001-10-18 NO NO20015063A patent/NO20015063L/no not_active Application Discontinuation
-
2002
- 2002-06-12 HK HK02104408A patent/HK1042850A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IS2161B (is) | 2006-11-15 |
EP1173205A1 (de) | 2002-01-23 |
EE200100545A (et) | 2003-02-17 |
HUP0200793A3 (en) | 2004-07-28 |
ATE296641T1 (de) | 2005-06-15 |
WO2000062810A1 (en) | 2000-10-26 |
NZ514264A (en) | 2003-10-31 |
SK15282001A3 (sk) | 2002-04-04 |
PT1173205E (pt) | 2005-10-31 |
HK1042850A1 (en) | 2002-08-30 |
EE04607B1 (et) | 2006-04-17 |
IL145871A0 (en) | 2002-07-25 |
ZA200108539B (en) | 2003-01-17 |
BR0009835A (pt) | 2002-01-08 |
HUP0200793A2 (hu) | 2002-07-29 |
CA2379105A1 (en) | 2000-10-26 |
AU4633500A (en) | 2000-11-02 |
DE60020551T2 (de) | 2006-03-23 |
SI1173205T1 (en) | 2005-10-31 |
SE9901387D0 (sv) | 1999-04-19 |
JP2002542208A (ja) | 2002-12-10 |
CN1348384A (zh) | 2002-05-08 |
CZ20013743A3 (cs) | 2002-01-16 |
PL351186A1 (en) | 2003-03-24 |
KR20010108516A (ko) | 2001-12-07 |
TR200103033T2 (tr) | 2002-03-21 |
EP1173205B1 (de) | 2005-06-01 |
IS6109A (is) | 2001-10-16 |
AU767425B2 (en) | 2003-11-13 |
NO20015063L (no) | 2001-10-18 |
DK1173205T3 (da) | 2005-08-08 |
ES2241603T3 (es) | 2005-11-01 |
DE60020551D1 (de) | 2005-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20015063L (no) | En oral formulering for administrering til ileum omfattende en inhibitorforbindelse til ileal-gallesyre transporten | |
SE0003766D0 (sv) | Novel formulation | |
BG105568A (en) | Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent | |
HUP9803044A2 (hu) | Ibuprofentartalmú készítmény | |
CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
EE200200086A (et) | Reniin-angiotensiini süsteemi inhibiitori kasutamine, kombineeritud produkt ja meetod kardiovaskulaarsete haigusjuhtude ärahoidmiseks | |
EP1545621A4 (de) | Träger | |
NO20001673L (no) | Farmasøytiske blandinger for oral administrering av molekylært jod | |
BG105570A (en) | Pharmaceutical compositions for modified release insulin sensitiser | |
TW349865B (en) | Therapeutic agent for hemorrhoidal diseases | |
AP1485A (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin. | |
CA2361081A1 (en) | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis | |
CA2331414A1 (en) | Transdermal therapeutic system for the administration of candesartan | |
JP2002500181A5 (de) | ||
BG108144A (en) | New use | |
EP1347754A4 (de) | Zusammensetzungen zur verhinderung der adhäsion | |
AU2003241629A1 (en) | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport | |
DE69814669D1 (de) | Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten | |
UA4313U (uk) | Спосіб лікування системного червоного вовчака | |
MY132962A (en) | Inotropic agents with negative chronotropic and vasodilatory effects | |
TR200102245T2 (tr) | Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem. | |
UA39418A (uk) | Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori | |
UA38434A (uk) | Спосіб лікування пептичної виразки шлунка |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |